Oncocyte Q2 Earnings Call Highlights

Impact · against what's priced in

IMDX faces increased regulatory and financial risk as the FDA requests additional data and quarterly cash burn projections rise to $8 million. While expanded Medicare reimbursement provides a positive market tailwind, the regulatory uncertainty and accelerated spend create a net negative short-term outlook.

IMDX−0.10

No priced-in read yet

In context

The FDA's request for more data and clarification on GraftAssureDx introduces regulatory risk, compounded by a rise in projected cash burn to $8 million per quarter from $6 million. These headwinds are partially offset by Medicare increasing covered surveillance tests from eight to 14, broadening the addressable market.

• cash burn▲400%
• healthcare
• biotech
• IMDX
• diagnostics
• european union
• fda
• kidney transplant
• medical devices